We’re pursuing potential breakthroughs to make a difference in the lives of cancer patients by improving survival and reducing chemotherapy induced peripheral neuropathy.
Our unique biologic leverages sphingolipid metabolism to target metastatic colorectal cancer while simultaneously addressing the neuropathic pain current treatments often cause
Colorectal cancer, the second leading cause of death among cancers, is associated with late-stage diagnosis, poor outcomes, and challenging side effects from current treatment options. BXQ-350 has the potential to redefine metastatic colorectal cancer (mCRC) treatment with encouraging Phase 1b/2a data in first line mCRC.
Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is advancing a new class of biologic therapy aimed at treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), with the potential to expand its portfolio into additional cancer types and broader neuropathic pain treatments. Bexion has generated promising Phase 1data across various solid tumor types, including colorectal cancer. The Company has completed enrollment in the open-label portion of its Phase 1b/2 trial, which evaluates BXQ-350 in combination with the standard of care for newly diagnosed patients with metastatic colorectal cancer (mCRC). Additionally, Bexion has completed proof-of-concept study for treating CIPN.
Bexion Pharmaceuticals is commited to innovating and developing unique patient centered therapeutics. With a multidisciplinary team of experts, Bexion is advancing a pipeline directed at treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN).